Arrowstreet Capital
ABUS icon

Arrowstreet Capital’s Arbutus Biopharma ABUS Stock Holding History

Arrowstreet Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,116
Closed -$169K – 1817
2025
Q4 		$169K Sell
35,116
-124,002
-78% -$558K ﹤0.01% 1784
2025
Q3 		$722K Buy
+159,118
New +$584K ﹤0.01% 1650
2020
Q3 		– Sell
-62,321
Closed -$113K – 2297
2020
Q2 		$113K Buy
+62,321
New +$102K ﹤0.01% 2215

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Arrowstreet Capital's ABUS Position: Q1 2026 in Review

Arrowstreet Capital sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 35,116 shares — an estimated $169K sold.

Arrowstreet Capital first reported a position in ABUS in Q2 2020 and held it in 3 quarters. The position peaked at $722K in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Arrowstreet Capital reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 35,116 Arbutus Biopharma shares in Q1 2026, an estimated $169K.
  • Arrowstreet Capital first reported a position in Arbutus Biopharma in Q2 2020 and held it in 3 quarters.
  • Arrowstreet Capital's Arbutus Biopharma position peaked at $722K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.